Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Glaukos (GKOS) Short-Term Debt repayments (2015)

Glaukos (GKOS) reported Short-Term Debt repayments of $1.8 million for Q4 2015, down 5.41% on a QoQ basis from $1.8 million in Q1 2015.

Glaukos (GKOS) has 1 years of Short-Term Debt repayments data on file, last reported at $1.8 million in Q4 2015.

  • Quarterly Short-Term Debt repayments changed N/A year-over-year to $1.8 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $3.6 million (changed N/A YoY) and the FY2015 annual result came in at $3.6 million, up 260.0% from the prior year.
  • Short-Term Debt repayments retreated to $1.8 million in Q4 2015 per GKOS's latest filing, from $1.8 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $1.8 million in Q1 2015 and bottomed at $1.8 million in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 259.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Glaukos 6.00 Bn 5.90 Bn 117.23 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2015 1.75 Mn
Dec 31, 2015 1.75 Mn
Mar 31, 2015 1.85 Mn
Mar 31, 2015 1.85 Mn